Down syndrome as risk factor for respiratory syncytial virus hospitalization: A prospective multicenter epidemiological study.
Respiratory syncytial virus (RSV) infection in childhood, particularly in premature infants, is associated with significant morbidity and mortality.



To compare the hospitalization rates due to RSV infection and severity of disease between infants with and without Down syndrome (DS) born at term and without other associated risk factors for severe RSV infection.



In a prospective multicentre epidemiological study, 93 infants were included in the DS cohort and 68 matched by sex and data of birth (±1 week) and were followed up to 1 year of age and during a complete RSV season.



The hospitalization rate for all acute respiratory infection was significantly higher in the DS cohort than in the non-DS cohort (44.1% vs 7.7%, P<.0001). Hospitalizations due to RSV were significantly more frequent in the DH cohort than in the non-DS cohort (9.7% vs 1.5%, P=.03). RSV prophylaxis was recorded in 33 (35.5%) infants with DS. The rate of hospitalization according to presence or absence of RSV immunoprophylaxis was 3.0% vs 15%, respectively.



Infants with DS showed a higher rate of hospitalization due to acute lower respiratory tract infection and RSV infection compared to non-DS infants. Including DS infants in recommendations for immunoprophylaxis of RSV disease should be considered.
Neonatology Division, Hospital Materno Infantil, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain.
Manuel
M
Sánchez-Luna
Cardiology Division, Hospital Materno Infantil, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain.
Constancio
C
Medrano
Social Pediatric Division, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
Julián
J
Lirio
D000208:Acute Disease / Q000453:epidemiology; D000998:Antiviral Agents / Q000627:therapeutic use; D004314:Down Syndrome / Q000150:complications* / Q000453:epidemiology / Q000821:virology*; D016021:Epidemiologic Studies; D005260:Female; D005500:Follow-Up Studies; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D000069455:Palivizumab / Q000627:therapeutic use; D011446:Prospective Studies; D018357:Respiratory Syncytial Virus Infections / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology* / Q000821:virology; D018113:Respiratory Syncytial Virus, Human / Q000302:isolation & purification; D012307:Risk Factors
D000998:Antiviral Agents; D000069455:Palivizumab
Down syndrome; hospitalization; palivizumab; prospective birth cohort study; respiratory syncytial virus